Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOD-1301
- Development stage
- Discontinued
- Lead developer
- OPKO Biologics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
MOD-1301 is a long-acting recombinant protein therapeutic developed by OPKO Biologics for the treatment of severe primary insulin-like growth factor 1 deficiency (SPIGFD). The drug utilizes proprietary Carboxyl Terminal Peptide (CTP) technology, which involves the fusion of CTP sequences derived from the human chorionic gonadotropin (hCG) beta subunit to the IGF-1 protein. This modification is designed to significantly extend the circulatory half-life of the therapeutic, potentially reducing the injection frequency required for hormone replacement therapy compared to standard daily IGF-1 formulations. MOD-1301 acts as an agonist at the IGF-1 receptor (IGF1R), promoting linear growth and addressing metabolic abnormalities in patients with SPIGFD, a condition characterized by extreme short stature and resistance to growth hormone. While the MOD-1301 program was discontinued, a related asset, OPK-8801002, remains in preclinical development for the same indication.
- Other names
- Long-acting IGF-1-CTPCTP-modified IGF-1SPIGF1DSPIGF-1DSPIGF 1D
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on MOD-1301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOD-1301.